Related references
Note: Only part of the references are listed.Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
Chara Stavraka et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study
Jan P. Kleinjan et al.
ANTI-CANCER DRUGS (2019)
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M. Henricks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF CANCER (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Emergency Use of Uridine Triacetate for the Prevention and Treatment of Life-Threatening 5-Fluorouracil and Capecitabine Toxicity
Wen Wee Ma et al.
CANCER (2017)
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification
Michele Boisdron-Celle et al.
SEMINARS IN ONCOLOGY (2017)
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
Michele Boisdron-Celle et al.
SEMINARS IN ONCOLOGY (2017)
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer
Manon Launay et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients
Carin A. T. C. Lunenburg et al.
PHARMACOGENOMICS (2016)
Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience
Arvind Sahu et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
Vijay M. Patil et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule
Elena Magnani et al.
INTERNAL AND EMERGENCY MEDICINE (2013)
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a c.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
Andre B. P. van Kuilenburg et al.
CLINICAL PHARMACOKINETICS (2012)
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
Chen Guang Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
PharmGKB summary: fluoropyrimidine pathways
Caroline F. Thorn et al.
PHARMACOGENETICS AND GENOMICS (2011)
Share Paper
